This is a preview of subscription content, log in via an institution to check access.
References
Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008; 68(12): 1699–1709
European Medicines Agency. Pradaxa: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Aug 22]
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47(5): 285–95
Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005 Aug; 3(8): 1843–53
Eriksson BI, Dahl OE, Rosencher N. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov; 5(11): 2178–85
Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004 Sep; 2(9): 1573–80
Rights and permissions
About this article
Cite this article
Dabigatran etexilate: a guide to its use in preventing venous thromboembolic events. Drugs Ther. Perspect 25, 5–7 (2009). https://doi.org/10.2165/0042310-200925020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/0042310-200925020-00002